S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
California bill to have human drivers ride in autonomous trucks is vetoed by governor
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
California bill to have human drivers ride in autonomous trucks is vetoed by governor
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
California bill to have human drivers ride in autonomous trucks is vetoed by governor
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Birthplace of the atomic bomb braces for its biggest mission since the top-secret Manhattan Project
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Speaker McCarthy is giving hard-right Republicans what they want. But it never seems to be enough.
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
California bill to have human drivers ride in autonomous trucks is vetoed by governor
NYSEAMERICAN:MTNB

Matinas BioPharma (MTNB) Stock Forecast, Price & News

$0.13
0.00 (0.00%)
(As of 09/22/2023 ET)
Compare
Today's Range
$0.13
▼
$0.14
50-Day Range
N/A
52-Week Range
$0.11
▼
$0.89
Volume
143,943 shs
Average Volume
563,152 shs
Market Capitalization
$29.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00
ProfileAnalyst RatingsChartCompetitorsEarningsHeadlinesShort InterestSocial Media

Matinas BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2,138.8% Upside
$3.00 Price Target
Short Interest
Healthy
0.33% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.42mentions of Matinas BioPharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

See Top Rated MarketRank™ Stocks Here

MTNB stock logo

About Matinas BioPharma (NYSEAMERICAN:MTNB) Stock

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

MTNB Price History

MTNB Stock News Headlines

September 23, 2023 | finanznachrichten.de
Matinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
September 22, 2023 | finance.yahoo.com
Matinas BioPharma Announces Notification of NYSE American Continued Listing Deficiency
September 24, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
September 15, 2023 | americanbankingnews.com
Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) Short Interest Update
September 6, 2023 | finance.yahoo.com
Matinas BioPharma to Participate in the H.C. Wainwright Global Investment Conference
August 22, 2023 | finance.yahoo.com
Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
August 11, 2023 | finanznachrichten.de
Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 10, 2023 | finance.yahoo.com
Q2 2023 Matinas BioPharma Holdings Inc Earnings Call
September 24, 2023 | Chaikin Analytics (Ad)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
August 9, 2023 | finance.yahoo.com
Matinas BioPharma Reports Second Quarter 2023 Financial Results and Provides a Business Update
August 2, 2023 | finance.yahoo.com
Matinas BioPharma to Participate in the BTIG Virtual Biotechnology Conference 2023
July 26, 2023 | finance.yahoo.com
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2023 Financial Results and Provide a Business Update on August 9, 2023
May 12, 2023 | seekingalpha.com
Matinas Biopharma GAAP EPS of -$0.03 in-line, revenue of $1.1M beats by $0.8M
May 12, 2023 | markets.businessinsider.com
Maxim Group Remains a Buy on Matinas BioPharma (MTNB)
May 12, 2023 | msn.com
Recap: Matinas BioPharma Hldgs Q1 Earnings
May 11, 2023 | msn.com
Why Matinas BioPharma Stock Is Sinking Today
May 11, 2023 | finanznachrichten.de
Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
May 11, 2023 | finance.yahoo.com
Q1 2023 Matinas BioPharma Holdings Inc Earnings Call
May 11, 2023 | finance.yahoo.com
Matinas BioPharma to Present at the JMP Securities Life Sciences Conference on May 15, 2023
May 10, 2023 | finance.yahoo.com
Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates
May 10, 2023 | finance.yahoo.com
Matinas BioPharma Reports First Quarter 2023 Financial Results and Provides a Business Update
May 3, 2023 | finance.yahoo.com
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2023 Financial Results and Provide a Business Update on May 10, 2023
April 28, 2023 | proactiveinvestors.com
Matinas BioPharma shares lipid nanocrystal platform delivery for emerging anti-fungal drug
April 23, 2023 | benzinga.com
CTI BioPharma Stock (NASDAQ:CTIC), Analyst Ratings, Price Targets, Predictions
April 19, 2023 | msn.com
Matinas jumps 25% to hit four-month high on data for anti-fungal agent
April 18, 2023 | finance.yahoo.com
Compassionate Use Patient Treated with Matinas BioPharma’s MAT2203 and Showing Complete Clinical Resolution of Rare R. mucilaginosa Fungal Infection Featured in Oral Presentation at ECCMID
March 19, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and MoonLake Immunotherapeutics (MLTX)
See More Headlines
Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Company Calendar

Last Earnings
8/09/2023
Today
9/24/2023
Next Earnings (Estimated)
10/31/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:MTNB
CUSIP
N/A
CIK
N/A
Web
www.matinasbiopharma.com
Phone
(908) 484-8805
Fax
N/A
Employees
34
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+2,138.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,000,000.00
Net Margins
-479.18%
Pretax Margin
-641.50%
Return on Equity
-60.91%
Return on Assets
-50.22%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.27
Quick Ratio
9.27

Sales & Book Value

Annual Sales
$3.19 million
Price / Sales
9.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.17 per share
Price / Book
0.79

Miscellaneous

Outstanding Shares
217,260,000
Free Float
197,277,000
Market Cap
$29.11 million
Optionable
Not Optionable
Beta
2.02
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Jerome D. Jabbour J.D. (Age 49)
    Co-Founder, CEO, Pres & Director
    Comp: $881.5k
  • Dr. Theresa Matkovits Ph.D. (Age 56)
    Chief Devel. Officer
    Comp: $601k
  • Dr. James J. Ferguson FACC (Age 69)
    M.D., Chief Medical Officer
    Comp: $619.92k
  • Mr. Keith A. Kucinski CPA (Age 53)
    M.B.A., Chief Financial Officer
  • Dr. Hui Liu M.B.A. (Age 55)
    Ph.D., Chief Technology Officer
  • Mr. Frank Calamusa
    Exec. Director and Head of Manufacturing & Supply Chain
  • Mr. Thomas J. Hoover M.B.A. (Age 53)
    Chief Bus. Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













MTNB Stock - Frequently Asked Questions

Should I buy or sell Matinas BioPharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MTNB shares.
View MTNB analyst ratings or view top-rated stocks.

What is Matinas BioPharma's stock price forecast for 2023?

1 brokerages have issued 12 month price targets for Matinas BioPharma's stock. Their MTNB share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 2,138.8% from the stock's current price.
View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts.

How have MTNB shares performed in 2023?

Matinas BioPharma's stock was trading at $0.5563 at the beginning of 2023. Since then, MTNB stock has decreased by 75.9% and is now trading at $0.1340.
View the best growth stocks for 2023 here.

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 711,500 shares, a decrease of 38.1% from the August 15th total of 1,150,000 shares. Based on an average daily trading volume, of 660,900 shares, the short-interest ratio is presently 1.1 days.
View Matinas BioPharma's Short Interest.

When is Matinas BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 31st 2023.
View our MTNB earnings forecast.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) released its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.03) EPS for the quarter. Matinas BioPharma had a negative net margin of 479.18% and a negative trailing twelve-month return on equity of 60.91%.

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

Who are Matinas BioPharma's major shareholders?

Matinas BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (1.81%), Geode Capital Management LLC (0.90%), Neville Rodie & Shaw Inc. (0.53%), Wells Fargo & Company MN (0.26%) and Virtu Financial LLC (0.04%).
View institutional ownership trends.

How do I buy shares of Matinas BioPharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.13.

How much money does Matinas BioPharma make?

Matinas BioPharma (NYSEAMERICAN:MTNB) has a market capitalization of $29.11 million and generates $3.19 million in revenue each year. The company earns $-21,000,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The official website for the company is www.matinasbiopharma.com. The company can be reached via phone at (908) 484-8805 or via email at mtnb@jtcir.com.

This page (NYSEAMERICAN:MTNB) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -